<?xml version="1.0" encoding="UTF-8"?><ns2:project xmlns:ns1="http://gtr.rcuk.ac.uk/gtr/api" xmlns:ns2="http://gtr.rcuk.ac.uk/gtr/api/project" xmlns:ns3="http://gtr.rcuk.ac.uk/gtr/api/fund" xmlns:ns4="http://gtr.rcuk.ac.uk/gtr/api/person" xmlns:ns5="http://gtr.rcuk.ac.uk/gtr/api/project/outcome" xmlns:ns6="http://gtr.rcuk.ac.uk/gtr/api/organisation" ns1:created="2026-06-03T15:52:43Z" ns1:href="http://gtr.ukri.org/gtr/api/projects/2AECBF95-10AB-4D54-93C5-5F8E4B7201DE" ns1:id="2AECBF95-10AB-4D54-93C5-5F8E4B7201DE"><ns1:links><ns1:link ns1:href="http://gtr.ukri.org/gtr/api/persons/F6925BBC-2091-4766-AEB3-5C5DC604EC7C" ns1:rel="PM_PER"/><ns1:link ns1:href="http://gtr.ukri.org/gtr/api/organisations/A7AC1C9D-D54A-412B-99FB-CB3CA650E05F" ns1:rel="LEAD_ORG"/><ns1:link ns1:href="http://gtr.ukri.org/gtr/api/organisations/A7AC1C9D-D54A-412B-99FB-CB3CA650E05F" ns1:rel="PARTICIPANT_ORG"/><ns1:link ns1:href="http://gtr.ukri.org/gtr/api/organisations/C8767B21-C9FE-4D9C-A9B3-63C6F8C09BAE" ns1:rel="PARTICIPANT_ORG"/><ns1:link ns1:href="http://gtr.ukri.org/gtr/api/organisations/E04097D1-7386-4BEC-AB80-85F0EEB80CB2" ns1:rel="PARTICIPANT_ORG"/><ns1:link ns1:end="2023-08-30T23:00:00Z" ns1:href="http://gtr.ukri.org/gtr/api/funds/B9A87776-4C75-4513-B39F-9D384BE5687C" ns1:rel="FUND" ns1:start="2023-03-01T00:00:00Z"/></ns1:links><ns2:identifiers><ns2:identifier ns2:type="RCUK">10061354</ns2:identifier></ns2:identifiers><ns2:title>Quality Control Test Efficiency</ns2:title><ns2:status>Closed</ns2:status><ns2:grantCategory>Collaborative R&amp;D</ns2:grantCategory><ns2:leadFunder>Innovate UK</ns2:leadFunder><ns2:abstractText>Sphere Fluidics Limited is an established Life Sciences company based in Cambridge, UK. We provide tools for biopharmaceutical organisations which include instruments and cartridges based on novel microfluidics. This project addresses the speed and efficiency of a critical quality control test which is required to validate the Cyto-Mine single cell analysis system. The approach is expected to yield a 15X reduction in time, yielding significant cost savings for the business and helping our biopharmaceutical customers to complete their projects faster, bringing new therapeutics to market sooner.</ns2:abstractText></ns2:project>